# TheraRNA

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/therarna

- Industry: Biotechnology
- Headquarters: Nanjing, China
- Website: www.therarna.cn
- Total disclosed funding: $2.1M
- Latest round: Angel (Aug 24, 2021)
- Investors on record: 1

## About

Established in 2019 and based in Nanjing, China, TheraRNA operates as a biotechnology company that provides mRNA vaccine algorithm and LNP dosage form. In August 2021, TheraRNA raised CNY 14 million in angel funding led by Share Capital. The company cooperates with Beijing Cancer Hospital, Nanjing Well Pharmaceutical Group Co.,Ltd. and Second Hospital of Lanzhou University, etc. The core research team comes from University of Science and Technology of China, Chinese Academy of Sciences, University of Southern California and Boston University.

The company develops lipid nanoparticle (LNP) dosage form technology platform. Platform is divided into four series, which include mRNA synthesis platform, LNP delivery platform, tumor nascent antigen AI prediction and GMP process development. It provides mRNA anti-cancer vaccine drugs, infectious disease-related vaccines and veterinary vaccines.

## Funding rounds

- Angel, Aug 24, 2021, $2.1M — Share Capital

## Investors

- Share Capital (https://capitalatlas.ai/funds/share-capital) — Angel